J Caleb Snider1, Lance A Riley1, Noah T Mallory1, Matthew R Bersi1, Prachi Umbarkar2, Rekha Gautam1, Qinkun Zhang2, Anita Mahadevan-Jansen1, Antonis K Hatzopoulos3, Luc Maroteaux4,5,6, Hind Lal2, W David Merryman1. 1. Department of Biomedical Engineering, Vanderbilt University, Nashville, TN (J.C.S., L.A.R., N.T.M., M.R.B., R.G., A.M.-J., W.D.M.). 2. Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (P.U., Q.Z., H.L.). 3. Division of Cardiovascular Medicine, Department of Medicine and Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN (A.K.H.). 4. Institut National de la Sante et de la Recherche Medicale Unite Mixte de Recherche-S 1270, Paris, France (L.M.). 5. Sorbonne Universités, Paris, France (L.M.). 6. Institut du Fer à Moulin, Paris, France (L.M.).
Abstract
BACKGROUND: Myocardial infarction (MI) induces an intense injury response that ultimately generates a collagen-dominated scar. Although required to prevent ventricular rupture, the fibrotic process is often sustained in a manner detrimental to optimal recovery. Cardiac myofibroblasts are the cells tasked with depositing and remodeling collagen and are a prime target to limit the fibrotic process after MI. Serotonin 2B receptor (5-HT2B) signaling has been shown to be harmful in a variety of cardiopulmonary pathologies and could play an important role in mediating scar formation after MI. METHODS: We used 2 pharmacological antagonists to explore the effect of 5-HT2B inhibition on outcomes after MI and characterized the histological and microstructural changes involved in tissue remodeling. Inducible 5-HT2B ablation driven by Tcf21MCM and PostnMCM was used to evaluate resident cardiac fibroblast- and myofibroblast-specific contributions of 5-HT2B, respectively. RNA sequencing was used to motivate subsequent in vitro analyses to explore cardiac fibroblast phenotype. RESULTS: 5-HT2B antagonism preserved cardiac structure and function by facilitating a less fibrotic scar, indicated by decreased scar thickness and decreased border zone area. 5-HT2B antagonism resulted in collagen fiber redistribution to thinner collagen fibers that were more anisotropic, enhancing left ventricular contractility, whereas fibrotic tissue stiffness was decreased, limiting the hypertrophic response of uninjured cardiomyocytes. Using a tamoxifen-inducible Cre, we ablated 5-HT2B from Tcf21-lineage resident cardiac fibroblasts and saw similar improvements to the pharmacological approach. Tamoxifen-inducible Cre-mediated ablation of 5-HT2B after onset of injury in Postn-lineage myofibroblasts also improved cardiac outcomes. RNA sequencing and subsequent in vitro analyses corroborate a decrease in fibroblast proliferation, migration, and remodeling capabilities through alterations in Dnajb4 expression and Src phosphorylation. CONCLUSIONS: Together, our findings illustrate that 5-HT2B expression in either cardiac fibroblasts or activated myofibroblasts directly contributes to excessive scar formation, resulting in adverse remodeling and impaired cardiac function after MI.
BACKGROUND: Myocardial infarction (MI) induces an intense injury response that ultimately generates a collagen-dominated scar. Although required to prevent ventricular rupture, the fibrotic process is often sustained in a manner detrimental to optimal recovery. Cardiac myofibroblasts are the cells tasked with depositing and remodeling collagen and are a prime target to limit the fibrotic process after MI. Serotonin 2B receptor (5-HT2B) signaling has been shown to be harmful in a variety of cardiopulmonary pathologies and could play an important role in mediating scar formation after MI. METHODS: We used 2 pharmacological antagonists to explore the effect of 5-HT2B inhibition on outcomes after MI and characterized the histological and microstructural changes involved in tissue remodeling. Inducible 5-HT2B ablation driven by Tcf21MCM and PostnMCM was used to evaluate resident cardiac fibroblast- and myofibroblast-specific contributions of 5-HT2B, respectively. RNA sequencing was used to motivate subsequent in vitro analyses to explore cardiac fibroblast phenotype. RESULTS: 5-HT2B antagonism preserved cardiac structure and function by facilitating a less fibrotic scar, indicated by decreased scar thickness and decreased border zone area. 5-HT2B antagonism resulted in collagen fiber redistribution to thinner collagen fibers that were more anisotropic, enhancing left ventricular contractility, whereas fibrotic tissue stiffness was decreased, limiting the hypertrophic response of uninjured cardiomyocytes. Using a tamoxifen-inducible Cre, we ablated 5-HT2B from Tcf21-lineage resident cardiac fibroblasts and saw similar improvements to the pharmacological approach. Tamoxifen-inducible Cre-mediated ablation of 5-HT2B after onset of injury in Postn-lineage myofibroblasts also improved cardiac outcomes. RNA sequencing and subsequent in vitro analyses corroborate a decrease in fibroblast proliferation, migration, and remodeling capabilities through alterations in Dnajb4 expression and Src phosphorylation. CONCLUSIONS: Together, our findings illustrate that 5-HT2B expression in either cardiac fibroblasts or activated myofibroblasts directly contributes to excessive scar formation, resulting in adverse remodeling and impaired cardiac function after MI.
Authors: D W Bonhaus; L A Flippin; R J Greenhouse; S Jaime; C Rocha; M Dawson; K Van Natta; L K Chang; T Pulido-Rios; A Webber; E Leung; R M Eglen; G R Martin Journal: Br J Pharmacol Date: 1999-07 Impact factor: 8.739
Authors: Benjamin M Jackson; Joseph H Gorman; Ivan S Salgo; Sina L Moainie; Theodore Plappert; Martin St John-Sutton; L Henry Edmunds; Robert C Gorman Journal: Am J Physiol Heart Circ Physiol Date: 2002-10-31 Impact factor: 4.733
Authors: David Hassel; Tillman Dahme; Jeanette Erdmann; Benjamin Meder; Andreas Huge; Monika Stoll; Steffen Just; Alexander Hess; Philipp Ehlermann; Dieter Weichenhan; Matthias Grimmler; Henrike Liptau; Roland Hetzer; Vera Regitz-Zagrosek; Christine Fischer; Peter Nürnberg; Heribert Schunkert; Hugo A Katus; Wolfgang Rottbauer Journal: Nat Med Date: 2009-11-01 Impact factor: 53.440
Authors: Alexander R Pinto; Alexei Ilinykh; Malina J Ivey; Jill T Kuwabara; Michelle L D'Antoni; Ryan Debuque; Anjana Chandran; Lina Wang; Komal Arora; Nadia A Rosenthal; Michelle D Tallquist Journal: Circ Res Date: 2015-12-03 Impact factor: 17.367
Authors: Arnauld Belmer; Emily Quentin; Silvina L Diaz; Bruno P Guiard; Sebastian P Fernandez; Stéphane Doly; Sophie M Banas; Pothitos M Pitychoutis; Imane Moutkine; Aude Muzerelle; Anna Tchenio; Anne Roumier; Manuel Mameli; Luc Maroteaux Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853
Authors: Russell A Gould; Hamza Aziz; Courtney E Woods; Manuel Alejandro Seman-Senderos; Elizabeth Sparks; Christoph Preuss; Florian Wünnemann; Djahida Bedja; Cassandra R Moats; Sarah A McClymont; Rebecca Rose; Nara Sobreira; Hua Ling; Gretchen MacCarrick; Ajay Anand Kumar; Ilse Luyckx; Elyssa Cannaerts; Aline Verstraeten; Hanna M Björk; Ann-Cathrin Lehsau; Vinod Jaskula-Ranga; Henrik Lauridsen; Asad A Shah; Christopher L Bennett; Patrick T Ellinor; Honghuang Lin; Eric M Isselbacher; Christian Lacks Lino Cardenas; Jonathan T Butcher; G Chad Hughes; Mark E Lindsay; Luc Mertens; Anders Franco-Cereceda; Judith M A Verhagen; Marja Wessels; Salah A Mohamed; Per Eriksson; Seema Mital; Lut Van Laer; Bart L Loeys; Gregor Andelfinger; Andrew S McCallion; Harry C Dietz Journal: Nat Genet Date: 2018-11-19 Impact factor: 38.330
Authors: Prachi Umbarkar; Sultan Tousif; Anand P Singh; Joshua C Anderson; Qinkun Zhang; Michelle D Tallquist; James Woodgett; Hind Lal Journal: Circ Res Date: 2022-09-02 Impact factor: 23.213
Authors: Camryn L Johnson; Lance Riley; Matthew Bersi; MacRae F Linton; W David Merryman Journal: Am J Physiol Heart Circ Physiol Date: 2021-09-10 Impact factor: 5.125
Authors: Natalie A Noll; Lance A Riley; Christy S Moore; Lin Zhong; Mathew R Bersi; James D West; Roy Zent; W David Merryman Journal: Am J Physiol Heart Circ Physiol Date: 2022-03-25 Impact factor: 5.125
Authors: Haiting Chen; Lu Fan; Ningxin Peng; Yong Yin; Dan Mu; Jun Wang; Ran Meng; Jun Xie Journal: ACS Appl Mater Interfaces Date: 2022-08-29 Impact factor: 10.383